VivaVision Biotech, a developer of eye disease treatments, has submitted an IPO application to the Hong Kong Stock Exchange in a race against time to secure funding before cash reserves deplete. With only $5.2 million in cash as of September 2025 and quarterly burn rates of ~$6.3 million, the company must complete its IPO within months. Two core products have reached Phase Three trials, including a breakthrough therapy for eye inflammation, but the company faces intense competition in the dry eye disease market.

The precision medicine market is projected to grow from USD 110.68 billion in 2025 to USD 237.28 billion by 2031, with a CAGR of 13.58%. Growth is driven by AI integration, biomarker advancements, next-gen sequencing (35%+ market share), and expanding adoption of targeted oncology therapies. North America leads the market, while Asia-Pacific emerges as a high-growth region.

Abbott Laboratories is presented as a superior alternative to volatile cannabis stocks like Tilray, offering 54 consecutive years of dividend increases and expected 10% EPS growth in 2026. The company benefits from its pending $23 billion acquisition of Exact Sciences and new FDA-approved heart rhythm treatment, though it faces headwinds from FreeStyle Libre 3 product issues and flat diagnostics segment performance.

The global digestive health supplements market is projected to grow from USD 12.22 billion in 2025 to USD 25.83 billion by 2035, with a CAGR of 7.77%. Growth is driven by increasing prevalence of gastrointestinal disorders, rising consumer awareness about microbiome health, and a shift toward preventive healthcare. However, regulatory complexity and lack of standardization pose challenges to market expansion.

The global neuromodulation devices market is projected to grow from USD 7.8 billion in 2024 to USD 16.1 billion by 2032, driven by increasing prevalence of chronic neurological conditions, technological innovations, and supportive regulatory frameworks. North America leads with 55% market share, while Asia-Pacific emerges as the fastest-growing region with over 12% CAGR. Recent FDA approvals include ProlivRx for depression treatment and Medtronic's adaptive deep brain stimulation system for Parkinson's disease.

Abbott Laboratories announced a quarterly dividend of 63 cents per share, marking its 409th consecutive quarterly dividend since 1924. The dividend is payable May 15, 2026, to shareholders of record on April 15, 2026. Abbott has increased its dividend for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index.

The global tetracyclines market is experiencing steady growth at a CAGR of 5.23%, driven by broad-spectrum efficacy, cost-effectiveness, and expanding applications in respiratory infections, dermatology, and sexual health. Doxycycline dominates with 46.1% market share, while oral formulations lead with 64.0% share. Key growth drivers include rising antibiotic demand in veterinary and aquaculture sectors, emerging clinical applications like Doxy-PEP, and robust supply chains from China and India.

AbbVie and Medtronic are highlighted as exceptional healthcare dividend stocks with strong track records of consistent dividend growth. AbbVie, a Dividend King with 54 consecutive years of dividend increases, offers a 2.98% yield and has successfully transitioned from its Humira dependency to a diversified portfolio including Rinvoq and Skyrizi. Medtronic, the largest stand-alone medical device maker with a 2.76% yield, is expanding into smart devices and has raised its dividend for 48 consecutive years. Both companies maintain healthy free cash flow to support continued dividend growth.

A comprehensive market research report on over-the-counter and direct-to-consumer infectious disease diagnostics forecasts significant growth through 2029, driven by rapid testing technologies, privacy concerns, and digital accessibility. The report analyzes market trends across 15 countries, covering respiratory, STD, UTI, and other infectious disease testing channels, with profiles of 70+ diagnostic companies.

The global infant nutrition market is shifting from volume-based to value-driven growth, projected to reach $162.08 billion by 2035 at a 10.26% CAGR. Despite declining birth rates, premium formulations and specialized nutrition products are driving growth. Major players are investing heavily in domestic manufacturing, regulatory compliance, and product innovation, while safety recalls and consolidation reshape the competitive landscape.

The global transcatheter embolization and occlusion devices market is projected to grow from USD 5.93 billion in 2025 to USD 11.53 billion by 2033, expanding at a CAGR of 8.66%. Growth is driven by increasing adoption of minimally invasive procedures in oncology and neurovascular interventions, with North America leading at 38.12% market share and Asia Pacific showing the fastest growth at 9.25% CAGR.

Abbott Laboratories' stock fell nearly 10% after missing Q4 revenue expectations due to higher manufacturing costs in its nutrition segment. However, the analyst argues the sell-off was overdone, citing Abbott's strong EPS growth, accelerating 2026 revenue guidance (6.5-7.5% organic growth), diversified portfolio, and pending acquisition of Exact Sciences expected to close in Q2 2026, which could add a new cancer detection growth vertical.